GSDMB and cancer: Recent studies revealed that GSDMB has alternatively spliced variants, with the non-pyroptotic variants inhibiting the pyroptotic ones.23,24 Motivated by this trans inhibition mechanism, we tested a panel of GSDME N-terminal domain mutants, including some associated with cancer,21 and identified I217N as defective in inducing pyroptosis and capable of inhibiting the wildtype counterpart (Figure S3A).